Related by context. All words. (Click for frequent words.) 69 HER2 expression 67 prognostic markers 67 prognostic biomarker 67 mutated K ras 66 K ras mutations 66 DNA methylation patterns 66 predictive biomarker 66 multivariate Cox 66 prostate carcinoma 66 KRAS mutation status 65 prognostic marker 65 immunohistochemical 65 molecular biomarker 65 PITX2 methylation 65 prognostic indicator 65 deCODE AF TM 65 obstructive coronary artery 65 PCA3 gene 65 KRAS mutations 65 chemosensitivity 65 eTag assays 65 methylation markers 65 prognostic indicators 64 immunohistochemical staining 64 endophenotypes 64 Epigenomics proprietary 64 ABCB1 64 genetic biomarkers 64 prostate cancer CaP 64 splice variants 64 KRAS mutation 64 biomarker 64 micrometastasis 64 MSH2 64 Corus CAD 64 hematopoietic cancers 64 serum biomarkers 64 MAGE A3 ASCI 64 diagnostic biomarker 64 LRP5 63 p# biomarker 63 splice junctions 63 microsatellite instability 63 stratifying patients 63 AGTR1 63 hypermethylated 63 EGFR receptor 63 histological subtype 63 alkaline phosphatase ALP 63 rs# [002] 63 RRM1 63 progesterone receptor PR 63 GSTP1 63 thymidylate synthase TS 63 HER2 overexpression 63 mTOR inhibitors 63 molecular subtypes 63 Haptoglobin 63 T#I [002] 63 histologic subtype 63 gastric carcinoma 63 mTOR inhibition 63 miRview mets 63 hepatic fibrosis 63 UGT#A# 63 NPM1 63 lymph node metastasis 63 prospectively defined 63 BRAF V#E mutation 63 tumorigenicity 62 VKORC1 62 genetic loci 62 genomewide 62 c MYC 62 urothelial carcinoma 62 PARP inhibition 62 epithelial tumors 62 bisulfite sequencing 62 CD# expression [002] 62 pancreatic adenocarcinoma 62 prognostic significance 62 molecular biomarkers 62 tumor histology 62 invasive lobular 62 CYT# potent vascular disrupting 62 FCGR3A 62 differentiate squamous 62 ZNF# 62 peritoneal carcinomatosis 62 survivin expression 62 gene loci 62 locoregional recurrence 62 K RAS 62 CIN2 + 62 chromosomal aberrations 62 pharmacodynamic biomarkers 62 endoglin 62 quantitative gene expression 62 EGFR mutation status 62 putative biomarkers 62 precursor lesions 62 predictive biomarkers 62 HERmark 62 mucinous 62 kidney urologic 62 PKCi 62 MammaPrint R 62 KRAS mutant 62 microdeletions 62 IFRD1 62 HER2 positivity 62 immunohistochemical analysis 62 NSCLC tumors 62 metastatic pancreatic 62 SNP rs# [002] 62 genomic alterations 62 breast carcinomas 62 sarcomatoid 62 nodal metastasis 62 miRview squamous 62 etiologic 62 ABL1 61 distant metastasis 61 PNH patients 61 ductal adenocarcinoma 61 phenotypic expression 61 mutational status 61 FDG PET imaging 61 NMIBC 61 Septin9 61 adipogenic 61 VerifyNow P#Y# 61 clinicopathological features 61 multigene expression test 61 cytogenic 61 bronchopulmonary dysplasia BPD 61 thyroid carcinoma 61 Immunohistochemical staining 61 nodal metastases 61 lactate dehydrogenase LDH 61 PCa 61 subclinical atherosclerosis 61 biliary tract cancer 61 colorectal adenoma 61 cisplatin resistant 61 CYP#C# [002] 61 Eg5 61 metastatic gastric 61 chromosomal mutations 61 oral squamous cell 61 essential thrombocythemia 61 breast cancer subtypes 61 OnDose TM 61 TOP2A 61 gastric adenocarcinoma 61 thyroid nodules 61 VeriStrat 61 situ LCIS 61 cTnI 61 renal carcinoma 61 Fc gamma receptor 61 SNP rs# [001] 61 galectin 3 61 PSADT 61 monoclonal gammopathy 61 APOL1 61 prostate cancer PCa 61 univariate 61 MLH1 61 microRNA expression 61 pharmacogenetic 61 FDG PET scans 61 pCR 61 antiangiogenic agent 61 miRview ™ squamous 61 carcinoma HCC 61 gene polymorphisms 61 HER3 61 haematopoietic 61 APTIMA HPV 61 rs# [004] 61 rBChE 61 deCODE ProstateCancer TM 61 genotypic 61 immunoblotting 61 antitumor effect 61 ADAM# 61 unresectable tumors 61 APOE e4 61 prognostic variables 61 Leydig cells 61 colorectal carcinoma 61 miRview ® 61 node metastases 61 genomewide association studies 61 tests miRview TM 61 atherosclerosis regression 61 kinase inhibition 61 troponin T 60 Septin 9 60 MMP# 60 pharmacodynamic markers 60 response pCR 60 EUS FNA 60 serum aminotransferase levels 60 immunoregulatory 60 STK# gene 60 micrometastases 60 operable breast cancer 60 advanced adenoma 60 missense mutations 60 methylation patterns 60 FLT3 60 miR #a [001] 60 FDG-PET/CT 60 #beta HSD1 60 cardiac repolarization 60 Prognostic factors 60 HNSCC 60 antibody titer 60 Li Fraumeni 60 refractory chronic lymphocytic 60 somatic mutations 60 TMPRSS2 ERG fusion 60 echocardiographic parameters 60 KRAS variant 60 LHRH receptor positive 60 adjuvant systemic 60 TMPRSS2 ERG 60 F FDG PET 60 AGHD 60 clinicopathological 60 metabolomic profiling 60 multivariate logistic regression 60 thyroglobulin 60 pharmacodynamic PD 60 mda 7 60 NKX#.# 60 liver metastasis 60 percutaneous biopsy 60 HGPIN 60 CFTR gene 60 KRAS oncogene 60 PROLARIS 60 COX2 60 Oncotype DX colon cancer 60 HER2 neu 60 alpha1 antitrypsin deficiency 60 K ras 60 gefitinib Iressa 60 causal variants 60 preoperative diagnosis 60 poly ADP ribose polymerase 60 AML MDS 60 pain palliation 60 promoter methylation 60 Clusterin 60 vimentin 60 urine cytology 60 recurrent glioblastoma multiforme 60 FDG uptake 60 myeloproliferative disorders 60 Treg cell 60 prognostic biomarkers 60 molecular abnormalities 60 HMGCR 60 metastatic lymph nodes 60 epistasis 60 tumor recurrence 60 genetic variants associated 60 FGFR3 60 qRT PCR 60 tumor biopsies 60 BRAF mutations 60 quantitative RT PCR 60 multivariable Cox 60 DNA methylation markers 60 multivariate analyzes 60 BRCA mutation carriers 60 colorectal tumor 60 TLE3 60 genotype phenotype 60 chromosome #p#.# 60 microRNA profiling 60 abnormal p# 60 clinically localized prostate 60 causative genes 60 plasma kallikrein 60 CD# expression [001] 60 E#F# 60 splice variant 60 diagnostic prognostic 60 SSc 60 urate oxidase 60 HOMA IR 60 K ras gene 60 chromosome #p# [001] 60 STRIDE PD 60 atypical hyperplasia 60 lymphovascular invasion 60 preoperative staging 60 prostate carcinogenesis 60 PTPN# 60 EGFR HER2 60 biomarkers 60 AEG# 59 WT1 59 Cystatin C 59 telomerase activation 59 arteriography 59 differential gene expression 59 presymptomatic 59 NPM1 mutation 59 Stat5 59 Trofex 59 susceptibility gene 59 breast carcinoma 59 Septin9 biomarker 59 CpG island 59 nomograms 59 DNA methyltransferases 59 SLC#A# [002] 59 sarcosine 59 HIF PH inhibitors 59 FGFR2 59 invasive ductal 59 Lymph node 59 CA9 SCAN 59 protein tyrosine phosphatase 59 beta1 integrin 59 PALB2 59 specific antigen PSA 59 liver fibrosis 59 #F FDG PET 59 EGFR mutations 59 estrogen receptor ER 59 cervical carcinoma 59 papillary renal cell carcinoma 59 #q# deletion 59 syngeneic 59 inducible nitric oxide synthase 59 susceptibility locus 59 gastric cardia 59 EGFR pathway 59 biologic pathways 59 PROSTVAC VF 59 monogenic 59 isoform selective 59 myeloperoxidase 59 esophageal carcinoma 59 genetic polymorphisms 59 intact parathyroid hormone 59 aneuploidies 59 interleukin IL -# 59 p#INK#a 59 susceptibility loci 59 carcinoembryonic antigen 59 TMEM#B 59 troponins 59 p# MAPK 59 oncogenesis 59 clinicopathologic 59 neovascular 59 #p# [001] 59 multigene 59 IL#B 59 isotypes 59 ductal carcinomas 59 SPINK1 59 ADAMTS# 59 genomic biomarker 59 CYP#D# genotype 59 intraobserver 59 Tasigna prolongs 59 vitro assay 59 miRNA profiling 59 chromosomal regions 59 morphometric vertebral fractures 59 microRNA biomarkers 59 chromosomal rearrangement 59 MGd 59 glutamic acid decarboxylase 59 gastrointestinal stromal tumors GISTs 59 Immunohistochemical analysis 59 prognostic factor 59 antiangiogenic therapy 59 orthotopic model 59 underlying molecular mechanisms 59 cell adhesion molecule 59 NGAL 59 miRview TM mets 59 prostanoid 59 CTAP# Capsules 59 glial tumors 59 secretory phospholipase A2 sPLA2 59 genotypic resistance 59 pathophysiological mechanisms 59 clusterin 59 parathyroid carcinoma 59 CC genotype 59 metastatic malignant 59 miRNA expression 59 adjuvant therapies 59 metabolomic profiles 59 nonischemic 59 novel VDA molecule 59 Her2/neu 59 CyPath ® assay 59 APOE genotype 59 clinico pathological 59 cervical intraepithelial neoplasia 59 CYP#C# [001] 59 nonmetastatic 59 Prognostic 59 microdeletion 59 core needle biopsies 59 colorectal adenocarcinoma 59 gene amplification 59 quantitative trait loci 59 Hurthle cell 59 contralateral breast 59 variant allele 59 pituitary adenomas 59 pancreatic prostate 59 lobular carcinoma 59 autosomal 59 FGFs 59 viral tropism 59 gastric carcinogenesis 59 choroidal vasculopathy 59 squamous cell lung cancer 59 TGFBR1 * 6A 59 biochemical recurrence 59 Leydig cell 59 co receptor tropism 59 imatinib therapy 59 B7 H3 59 MET amplification 59 transcriptional profiling 59 A2 Lp PLA2 59 HERmark assay 59 lung metastasis 59 TET2 59 BRCA deficient 59 pelvic lymphadenectomy 59 PGDH 59 pancreatic carcinoma 59 osteoprotegerin 59 neuroregenerative 59 CSF Tf 59 deCODE BreastCancer TM 59 tumor subtypes 59 urothelial 59 FFR measurements 59 differentially expressed proteins 59 fallopian tube cancers 59 sentinel node 59 methylenetetrahydrofolate reductase 59 MSMB 59 histopathological 59 postoperative radiotherapy 59 aminotransferase 59 hematological relapse 59 Papillary 59 hematological parameters 59 vidofludimus 59 MYH9 gene 59 VEGF receptor 59 MAPK pathway 59 non coding RNA 58 ERK1 2 58 pharmacogenetic test 58 4E BP1 58 enzastaurin 58 p tau 58 BRAF V#E 58 galiximab 58 scintigraphic 58 p# mutations 58 mRCC 58 proteomic analysis 58 malignant transformation 58 germline mutations 58 ADPKD 58 ERCC1 58 non mutated KRAS 58 Sertoli cell 58 ovarian endometrial 58 IgA deficiency 58 genetic polymorphism 58 transcriptional regulation 58 FUS1 58 ChIP chip 58 premalignant lesions 58 nomogram 58 genomic profiling 58 GSTT1 58 malignant nodules 58 ELISpot 58 pre malignant lesions 58 pharmacogenetic testing 58 linkage disequilibrium 58 biologic plausibility 58 HER2 receptor 58 molecular markers 58 elevated CRP 58 STK# [002] 58 late onset hypogonadism 58 transcriptomics 58 castrate resistant prostate cancer 58 Genotypic 58 Ki# 58 #q#.# [002] 58 iPS derived 58 neuroligins 58 cMET 58 heterozygotes 58 Fas ligand 58 fusion enhancers 58 Prostate Cancer Progression 58 AVOREN 58 HepG2 cells 58 #.#ng/ml 58 lymphoid tumors 58 chromosome #q# [001] 58 Mammostrat 58 CDKN2A 58 antibody mediated 58 paternally inherited 58 NNRTI resistance 58 Cdc7 58 cTnT 58 Aspergillus nidulans 58 GSTM1 58 PD2i R 58 biomarker assay 58 nonsmall cell lung cancer 58 VEGF expression 58 breast cancer metastasis 58 Randomized clinical trials 58 CDH1 58 gene rearrangements 58 PTEN gene 58 Hedgehog inhibitor 58 ErbB2 positive 58 histopathologic 58 cytokeratin 58 tryptase 58 pretest probability 58 ELACYT 58 murine models 58 differentially expressed genes 58 immunofluorescent 58 S. maltophilia 58 CINQUIL 58 osteoblast 58 stem cell pluripotency 58 ovarian pancreatic 58 bladder tumors 58 Microarray analysis 58 TRAF1 C5 58 HER2 positive cancers 58 BRAF mutation 58 EGFR signaling 58 Drosha 58 pretransplant 58 transgene expression 58 monocyte chemoattractant protein 58 sensitivity specificity 58 lymphangiogenesis 58 alpha synuclein gene 58 Squamous 58 pelvic ultrasound 58 MTHFR 58 Azedra 58 FDG PET 58 nucleotide analog 58 lymphoid malignancies 58 humanised antibody 58 tolerability pharmacokinetics 58 nonclinical studies 58 CTEPH 58 mitochondrial DNA mtDNA 58 minimally symptomatic 58 anti angiogenic therapy 58 HIF 1a 58 hemodynamically significant 58 GNAQ 58 SMAD4 58 TCF#L# gene 58 alvespimycin 58 HAAH 58 diagnostic modality 58 Akt activation 58 elacytarabine 58 fluorodeoxyglucose positron emission tomography 58 interobserver reliability 58 low expressors 58 Chronic pancreatitis 58 prostate ovarian 58 Circulating tumor cells 58 radiochemotherapy 58 transcriptomes 58 pediatric malignancies 58 TTR gene 58 PDGF receptor 58 siRNA knockdown 58 TroVax ® 58 NuroPro R 58 cytolytic 58 relapsed MM 58 proton MR spectroscopy 58 sequence homology 58 therapeutic monoclonal antibody 58 bronchoalveolar lavage fluid 58 clefting 58 TP# gene 58 extramedullary 58 hormone receptor status 58 MiCK assay 58 adenoma 58 cardiac troponin T 58 cytologic 58 multivariable analysis 58 quantitate 58 tumor hypoxia 58 PSA nadir 58 rhIGFBP 3 58 pretreatment serum 58 PRIMO CABG 58 RT qPCR 58 squamous 58 androgen receptor AR 58 biochemical marker 58 K ras mutation 58 virulence genes 58 histologies 58 aerodigestive tract 58 HLA DQ2 58 CHEK2 58 serologic 58 HLA DRB1 58 p# activation 58 tumor subtype 58 PCA3 58 angiographically 58 completely resected 58 SELDI TOF MS 58 TPMT 58 TMEM density 58 gastric carcinomas 58 advanced neoplasia 58 MTT assay 58 sCJD 58 aurora kinase 58 LungAlert TM 58 pulmonary nodules 58 molecular profiling 58 nonalcoholic steatohepatitis NASH 58 uricase 58 D dimer 58 adenomatous 58 MDRD equation 58 Multivariate analysis 58 normal karyotype 58 thyroid stimulating hormone 58 EGFR tyrosine kinase inhibitors 58 TIMP 1 58 CCR1 58 CYP#A# CYP#D# 58 CD# CEA 58 p# biomarkers 58 KIAA# 58 ChIP Seq 58 EGFR TKIs 58 thymoma 58 penetrance 58 plasma pharmacokinetics 58 neratinib 58 radiographic outcomes 58 pancreatic endocrine 58 tubulin inhibitor 58 myocardial necrosis 58 inactivating mutations 58 serum PSA 58 ASCUS 58 validate biomarkers 58 histological subtypes 58 sporadic ALS 58 pathogenetic 58 SLN biopsy 58 EDEMA3 trial 58 PCA3 prostate cancer 58 cardioprotective effects 58 T1a 58 proto oncogene 58 ALK inhibitors 58 Oncotype DX Recurrence Score 58 Lp PLA 2 58 Micro RNAs 58 resected pancreatic cancer 58 CCR3 58 IGF IR 58 mutated p# 58 E cadherin expression 58 BRCA2 mutation carriers 58 tumoral 58 lung adenocarcinomas 58 Flow cytometry 58 paraganglioma 58 chemoresistant 57 HER2 amplification 57 thymidylate synthase 57 mRNA transcripts 57 ENMD # 57 cilengitide 57 GIST tumors 57 thyrotropin 57 skin sterol 57 silico prediction 57 CDK inhibitor 57 ERBB2 57 schizophrenia CIAS 57 precancerous condition 57 FGFR4 57 prostate adenocarcinoma 57 mutant BRAF 57 CEACAM1 57 C telopeptide 57 familial ALS 57 NPM1 mutations 57 pT3 57 GRNCM1 57 HER2 gene 57 chromosome #q# [002] 57 Darapladib 57 HNPCC 57 advanced adenomas 57 ependymoma 57 radiosensitivity 57 thoracoscopic lobectomy 57 tumors GIST 57 conditional logistic regression 57 Estrogen Receptor 57 neutrophil gelatinase associated lipocalin 57 HIV HCV coinfected 57 C#T [002] 57 Zevalin consolidation 57 genomic biomarkers 57 EAAT2 57 FLT3 mutations 57 thyrotropin levels 57 androgen independent 57 PD2i algorithm 57 epigenetic mechanisms 57 Logistic regression 57 Kaplan Meier analysis 57 Anticalins ® 57 DNA methylation biomarker 57 LRAT 57 pigmented skin lesions 57 risk stratification 57 bladder ovarian 57 locoregional 57 prognostically 57 atherogenic dyslipidemia 57 DAS# CRP 57 visit www.genenews.com 57 alpha fetoprotein AFP 57 Endometrial 57 IGFBP2 57 Raf MEK ERK 57 dysbindin 57 Kufs disease 57 Xanafide 57 hTERT 57 stratify patients 57 colorectal gastric 57 neurodevelopmental outcome 57 KRAS mutations occur 57 coronary artery stenosis 57 NF kB pathway 57 p# mutation 57 prion infection 57 malignant lymphoma 57 leukocyte count 57 florbetaben 57 bladder carcinoma 57 PI3K/Akt pathway inhibitor 57 #q# [001] 57 TLR9 agonists 57 hamartomas 57 CellSearch System 57 urothelial cancer 57 atypia 57 HG PIN 57 p# mitogen activated 57 TCF#L# 57 Gleevec resistant 57 MR spectroscopy 57 CSF biomarkers 57 qualitative serum 57 lactate dehydrogenase 57 HOXB# 57 PIGF 57 carotid bruit 57 resectable pancreatic cancer 57 Leukemias 57 PTEN protein 57 immunohistochemistry IHC 57 benign ovarian 57 Ceflatonin 57 mRNA expression 57 myocardial infarct size 57 steroidogenic 57 metaplasia 57 JAK3 57 proteomic biomarkers 57 immunoblot 57 metastatic prostate 57 statistical significance p 57 adrenocortical cancer 57 precancerous tissues 57 polycythemia vera PV 57 resistin 57 activating mutations 57 microglial 57 BCL2 57 CDK4 57 Cardiorespiratory fitness 57 beta islets 57 mammographic density 57 TNF blocker therapy 57 hypoxia inducible factor 57 tumor xenograft models 57 bronchoalveolar lavage 57 BEXXAR Therapeutic Regimen 57 acute myeloid 57 activating mutation 57 mutant allele 57 serum biomarker 57 haematologic 57 sDNA 57 BRCA1 BRCA2 57 Symadex 57 miRNA biomarkers 57 causative mutations 57 progesterone receptor 57 R0 resection 57 Factor Receptor 57 cAMP signaling 57 CYP#D# gene 57 human leukocyte antigens 57 Cervista HPV HR 57 endothelial activation 57 pulmonary metastases 57 Immunohistochemistry IHC 57 angiographic outcomes 57 demonstrated antitumor activity 57 XmAb# 57 hyperplastic polyps 57 chemopreventive agent 57 T2 lesions 57 anti JCV antibodies 57 kidney allograft 57 VEGF inhibitors 57 idiopathic myelofibrosis 57 morphologic 57 pulmonary metastasis 57 GAMMAGARD 57 coagulation abnormalities 57 Upregulation 57 fine needle aspiration 57 amyloid cascade 57 serum protein biomarkers 57 Affibody ® molecules 57 #q#.# [001] 57 precancerous cervical 57 soluble CD# ligand 57 HER2 HER2 57 Wnt signaling pathway 57 Western blotting 57 HIF 1α 57 cytolytic activity 57 node metastasis 57 Galectin 3 57 chemokine receptor 57 humoral responses 57 MCF7 57 genetic modifiers 57 sentinel nodes 57 epigenetic regulation 57 distant metastases 57 ncRNA 57 nodal dissection 57 histone modifications 57 abnormal glucose metabolism 57 CaP 57 virological response 57 N telopeptide 57 biochemical relapse 57 #q# deletion syndrome 57 invasive carcinoma 57 prognostic 57 RBP4 57 HepDirect prodrug 57 eosinophil count 57 OGG1 57 hypokalemia hypomagnesemia 57 underwent resection 57 mosaicism 57 Rb#/p# 57 PCNSL 57 humanised monoclonal antibody 57 PIK3CA 57 neoplasm 57 CHD7 57 non squamous NSCLC 57 myeloproliferative 57 epithelial ovarian cancer 57 axillary lymph node 57 coronary stenosis 57 axillary lymph nodes 57 recurrent ovarian 57 unmeasured confounders 57 cytogenetic 57 HER2 amplified 57 p# INK4a 57 gene expression biomarkers 57 intima media thickness 57 whose tumors overexpress 57 FGFR1 57 NuroPro PD 57 engineered RAP peptides 57 erythropoietic 57 airway hyperresponsiveness 57 CagA 57 PD2i ® 57 benign moles 57 pathologic fracture 57 squamous intraepithelial lesions 57 endometrial hyperplasia 57 lung pancreatic 57 hENT1 57 Her2 positive 57 genes CYP#C# 57 SUVmax 57 thyroid peroxidase 57 eotaxin 57 JAK2 mutation 57 heparanase 57 colorectal tumors 57 OvaRex MAb 57 HbF 57 transabdominal 57 ADVEXIN therapy 57 postoperative pathology 57 Six3 57 bFGF 57 ATL# [001] 57 immunostaining 57 ovarian carcinoma 57 prospective multicenter study 57 DLX5 57 grade squamous intraepithelial 57 interferon beta therapy 57 DNA rearrangements 57 TOMM# 57 ZACTIMA 57 BioMAP ® Systems 57 mertansine 57 proteoglycan 57 immunofluorescence staining 57 KRAS wild 57 BioMAP 57 Octreolin 57 chromosomal anomalies 57 thyroid carcinomas 57 substrate specificity 57 intestinal polyps 57 myocardial viability 57 intracranial hemorrhage ICH 57 pharmacodynamic parameters 57 endometrioid 57 tests miRview ™ 57 JAK2 inhibitor 57 5 HT2A serotonin 57 epithelial tissues 57 C1q 57 transcriptome sequencing 57 ZFP TF 57 acadesine 57 multicenter Phase II 57 EGFR mutation positive 57 platelet function 57 lung adenocarcinoma 57 Archexin 57 methyltransferase 57 nucleotide substitutions